1	Dose-respo	onse effect of dietary nitrate on muscle contractility
2		and blood pressure in older subjects
3		
4		
5	Edgar J. C	Gallardo ¹ , Derrick A. Gray ¹ , Richard L. Hoffman ¹ ,
6	¹ Brandon A.	Yates, ² Ranjani N. Moorthi, and Andrew R. Coggan ¹
7		
8		
9	¹ Department of	of Kinesiology, School of Health and Human Science,
10	and ² Depa	artment of Internal Medicine, School of Medicine,
11	India	na University Purdue University Indianapolis
12		Indianapolis, IN 46112
13		
14		
15	Address correspondence to:	Andrew R. Coggan, PhD
16		Department of Kinesiology
17		Indiana University Purdue University Indianapolis
18		IF 101C, 250 University Boulevard
19		Indianapolis, IN 46112
20		Phone: (317) 274-0656
21		Fax: (317) 274-2041
22		e-mail: <u>acoggan@iupui.edu</u>

23 Abstract

24 **Purpose:** We have recently demonstrated that dietary nitrate, a source of nitric oxide via the 25 enterosalivary pathway, can improve muscle contractile function in healthy older men and 26 women. Nitrate ingestion has also been shown to reduce blood pressure in some, but not all, 27 studies of older individuals. However, the optimal dose for eliciting these beneficial effects is 28 unknown. Methods: A randomized, double-blind, placebo-controlled crossover study was 29 performed to determine the effects of ingesting 3.3 mL/kg of concentrated beetroot juice (BRJ) 30 containing 0, 200, or 400 µmol/kg of nitrate in nine healthy older subjects (one man, eight 31 women; mean age 70 ± 1 y). Maximal knee extensor power (Pmax) and speed (Vmax) were 32 measured 2 h after BRJ ingestion using isokinetic dynamometry. Blood pressure was monitored 33 periodically throughout each study. **Results:** Pmax (in W/kg) was higher (P<0.05) after the low 34 dose (3.9 ± 0.4) compared to the placebo (3.7 ± 0.4) or high dose (3.7 ± 0.4) . Vmax (in rad/s) also 35 tended higher (P=0.08) in the low (11.9 \pm 0.7) compared to the placebo (10.8 \pm 0.8) or high dose 36 (11.2±0.8) trials. Eight out of nine subjects achieved a higher Pmax and Vmax after the lower vs. 37 the higher dose. These dose-related changes in muscle contractility paralleled changes in nitric oxide (NO) bioavailability, as reflected by changes in breath NO and plasma 3-nitrotyrosine 38 39 levels. No significant changes were found in systolic, diastolic, or mean arterial pressure. 40 **Conclusions:** Varying doses of dietary nitrate have differential effects on muscle function and 41 blood pressure in older individuals. A moderate dose of nitrate increases muscle speed and 42 power, but these improvements are lost at a higher dose. Blood pressure, on the other hand, is not 43 reduced even with a higher dose.

44



46 Roughly $\frac{1}{3}$ of individuals over age 65 y suffer from some form of ambulatory or self-care 47 disability (1). In the United States alone, this amounts to some 15 million individuals at present, 48 a number is likely to at least double over the next three decades (1). Similar trends are evident 49 world-wide (1). The primary cause of disability in older persons is a decline in muscle contractile 50 function, with serious difficulty walking or climbing stairs being the most prevalent problem at all ages (1). These functional limitations are highly predictive of dependence, institutionalization, 51 52 and mortality in the elderly (2,3). Thus, it is clear that age-related changes in muscle function can 53 have an enormous impact not only on a given individual's quality and length of life but also on 54 the societal costs of caring for an aging population.

55 Numerous factors contribute to the decline in muscle contractile function with aging. 56 These include a reduction in overall muscle mass, as a result of a decrease in both muscle fiber 57 number and size, as well as alterations in the neural control of muscle (4,5). These contribute to a 58 decrease in strength, i.e., a reduction in the maximal force-generating capacity of muscle. 59 However, the maximal speed of muscle shortening also decreases with aging (6-9), leading to an 60 even more dramatic age-related decline in maximal muscle power, i.e., the product of force and speed (7,8). Moreover, decreases in muscle power with aging are a better predictor of movement 61 disabilities than decreases in strength (9,10). Improving muscle speed and power should 62 63 therefore logically be the primary focus of any intervention intended to combat muscle 64 dysfunction in the elderly.

We have previously reported that dietary nitrate (NO_3^-), a source of nitric oxide (NO) via the reduction of NO_3^- to nitrite (NO_2^-) and hence to NO via the action of bacterial $NO_3^$ reductases in the mouth and/or mammalian NO_3^- reductases (e.g., xanthine oxidase (XOR)) in the tissues (10), can significantly enhance muscle speed and power in various subject

69 populations, i.e., healthy young and middle-aged individuals (11,12), athletes (13), patients with 70 heart failure (14). Although the exact mechanisms responsible for this effect are still uncertain, they appear to involve NO-mediated changes in muscle calcium (Ca^{2+}) release and/or sensitivity 71 72 (15). More recently, we have demonstrated that acute NO_3^{-1} ingestion also significantly improves 73 muscle speed and power in healthy elderly subjects (16). These changes were large enough to 74 theoretically offset the reductions resulting from several decades of aging. It is therefore clear 75 that dietary NO_3^{-1} supplementation holds enormous potential as a means of mitigating muscle 76 dysfunction, and hence disability, in older individuals. The optimal dose of NO_3^{-1} for eliciting 77 improvements in muscle contractility in elderly persons, however, has not been determined.

78 In addition to improving muscle function, dietary NO₃⁻ supplementation has also been 79 found to reduce blood pressure in a number of subject groups (17). However, a recent meta-80 analysis concluded that dietary NO₃⁻ does not reduce blood pressure in subjects ≥ 65 y of age 81 (18). It was hypothesized that this may be due to variations in the oral microbiota and/or other 82 factors (e.g., gastric acid production) that could influence the extent of reduction of NO_3^- to NO_2^- 83 (18). Alternatively, an age-related decline in the expression of the putative NO_3^{-1} transporter 84 sialin could limit the ability of the salivary glands of older individuals to concentrate and re-85 secrete NO_3^- into the oral cavity (19). In either case, larger doses of NO_3^- may be required to 86 elicit significant increases in plasma NO_2^{-1} levels and NO bioavailability, and hence a decrease in 87 blood pressure, in older persons. As with muscle function, however, the effect of NO_3^- dose on 88 changes in blood pressure in older individuals has not been tested.

The purpose of the present study was to determine the effects of varying doses of dietary NO₃⁻ on changes in muscle speed and power and blood pressure in healthy older men and women. Based on previous research (20), we hypothesized that a moderate dose of NO₃⁻ would

4

92 increase muscle speed and power in such individuals, which would not be further enhanced at a 93 higher dose of NO_3^- . Blood pressure, on the hand, would only be significantly reduced at a 94 higher dose of NO_3^- .

95 Methods

96 Subjects: Nine healthy, community-dwelling older subjects (one man, eight women) with mean 97 (±SE) age, height, weight, and body mass index of 70±1 y, 1.68±0.03 m, 68.7±4.2 kg, and 24.3 ± 1.3 kg/m² participated in this study. Potential subjects were assessed during an initial visit 98 99 to the Clinical Research Center that included a health history and physical examination, resting 100 electrocardiogram, phlebotomy for determination of screening/phenotyping laboratories (CBC, 101 CMP, fasting insulin and lipids), and practicing the entire isokinetic dynamometry testing 102 protocol (see below). Individuals were excluded if they met any of the following criteria: not 103 between the ages of 65-79 y, unable to provide informed consent, were pregnant or lactating, had 104 a history of major metabolic (Type I or II diabetes, thyroid disorders), neuromuscular (e.g., 105 cervical spondylotic radiculomyelpathy, lumbar spondylosis, amyotrophic lateral sclerosis, 106 Guillain-Barré syndrome, acquired demyelinating polyneuropathies), cardiovascular (e.g., 107 moderate or severe valvular disease, myocardial infarction/ischemia, myocardial/pericardial disease, stage II or greater hypertension, heart failure), renal (eGFR <60 mL/min/1.73 m² or 61-108 90 mL/min/1.73m² and albumin:creatine ratio >30), or liver (i.e., SGOT/SGPT > 2x normal) 109 110 disease, were anemic (hematocrit <30%), or had any other contraindications to vigorous 111 exercise. They were also excluded from the study if they currently smoked or were taking proton 112 pump inhibitors, antacids, xanthine oxidase inhibitors, or were on hormone replacement therapy, 113 as these can interfere with the reduction of NO_3^- to NO_2^- and then NO (21-23). Individuals on 114 phosphodiesterase inhibitors were also excluded, as these can potentiate the effects of NO (24).

115 The study was approved by the Human Subjects Office at Indiana University, and written,116 informed consent was obtained from each subject.

117 *Experimental design and protocol:* Following completion of the initial screening visit, eligible 118 volunteers were studied using a randomized, double-blind, placebo-controlled crossover design. 119 They were asked to avoid sympathetic stimulation (caffeine, alcohol) and fast for 12 h prior to 120 testing. Upon arrival at the University Hospital Clinical Research Center (CRC), blood pressure, 121 heart rate, and the amount of NO in the breath were measured. An intravenous catheter was then 122 placed, and a baseline blood sample was obtained for subsequent determination of plasma NO_3^{-1} 123 and NO₂⁻ concentrations as described below. The subject then ingested 3.3 mL/kg of a commercial concentrated beetroot juice (BRJ) supplementation (Beet It Sport[®], James White 124 125 Drinks, Ipswich, UK) either: 1) essentially devoid of NO₃⁻ (placebo); 2) containing (based on 126 direct measurement) 121 μ mol/mL NO₃⁻ (thus total dose = 400 μ mol/kg); or 3) an equal mixture 127 of the placebo and NO_3^- containing BRJ products (total dose = 200 μ mol/kg). Hemodynamic 128 data and breath/blood samples were collected again after 1 and 2 h of quiet rest, after which 129 muscle contractile function was determined as described below. After a 10 min recovery period, 130 heart rate and blood pressure were again measured and the final breath and blood samples were 131 collected, then the subject was fed lunch and released from the CRC. They subsequently returned 132 to the hospital and repeated the above procedures two more times receiving the other doses, with 133 a 1-2 wk washout period between visits.

Measurement of muscle contractile function: Maximal knee extensor power (Pmax, in W/kg) and velocity (Vmax, in rad/s) were measured using an isokinetic dynamometer (Biodex System 4 Pro[®], Biodex Medical Systems, Shirley, NY) as previously described in detail (11). Briefly, the femoral condyle of the subject's dominant leg was aligned with the axis of rotation of the

138 dynamometer and their torso, waist, thigh, and lower leg tightly restrained with straps to prevent 139 extraneous movement. The subject then performed maximal knee extensions at angular velocities 140 spanning the ascending limb of the power-velocity relationship, i.e., at 0, 1.57, 3.14, 4.71, and 141 6.28 rad/s (0, 90, 180, 270, and 360 % sec). Three maximal repetitions were executed at each velocity, with 2 min of rest allowed between each set of contractions. Subjects were instructed to 142 143 attempt to move as quickly and as forcefully as possible during each repetition, and strong verbal 144 encouragement was provided throughout the testing. To eliminate artifacts, the isokinetic 145 dynamometer data were windowed, filtered, and smoothed as previously described (11), after 146 which peak power at each velocity was calculated by multiplying the peak torque by velocity. 147 Pmax and Vmax were then determined by fitting an inverted parabola to the peak power-velocity 148 relationship (11).

149 Measurement of breath NO and plasma NO₃⁻, NO₂⁻, and 3-NT: Breath NO was measured using a portable electrochemical analyzer (NIOX VERO[®], Circassia Pharmaceuticals, Mooresville, NC). 150 151 Plasma NO₃⁻ and NO₂⁻ were measured using a dedicated high performance liquid 152 chromatography system (ENO-30, Eicom USA, San Diego, CA) as previously described in detail 153 (25). Briefly, 25 µL of thawed plasma was mixed 1:1 with methanol, centrifuged at 4°C for 10 154 minutes at 10,000 g, and a 10 µL aliquot of the protein-poor supernatant injected into the HPLC. 155 Plasma NO₃⁻ and NO₂⁻ concentrations were calculated based on standard curves generated using 156 NIST-traceable standard solutions. Plasma 3-NT levels were determined using a commercial ELISA kit (OxiSelect[™], Cell Biolabs, San Diego, CA). 157

158 *Sample size:* The required sample sizes to detect changes in Pmax and Vmax (the primary 159 outcome variables) were estimated based on the respective effect sizes observed in our recent 160 study (16) and assuming $\alpha = 0.05$ and $1-\beta = 0.90$. These calculations indicated that n=11 would

7

be required to detect changes in Pmax, whereas n=6 would be required to detect changes in Vmax. However, we were only able to study n=9 subjects before all non-essential research at our institution was halted due to the COVID-19 pandemic.

164 Statistical analyses: Statistical analyses were performed using GraphPad Prism version 8.4.1 165 (GraphPad Software, La Jolla, CA). Normality of data distribution was tested using the 166 D'Agostino-Pearson omnibus test. Peak torque/power data and hemodynamic, breath NO, 167 plasma NO_3^- , NO_2^- , and 3-NT data were analyzed using two-way (i.e., dose x velocity or dose x 168 time, respectively) repeated measures ANOVA. Changes from baseline (average of 2 h and 10 169 min post-exercise values) in the latter variables as well as absolute values and changes in Vmax 170 and Pmax were analyzed using one-way ANOVA. Post-hoc testing was performed using the 171 Holm-Šidák multiple comparison procedure. P<0.05 was considered significant.

172 **Results**

173 Markers of NO bioavailability: Plasma NO₃⁻ and NO₂⁻ concentrations and breath NO levels did 174 not change following ingestion of the placebo BRJ, whereas ingestion of BRJ containing 200 175 μ mol/kg of NO₃⁻ resulted in marked elevations in all three (Table 1, Fig. 1A-C). The magnitude 176 of the increases in plasma NO_3^- and NO_2^- over baseline were comparable to those observed in 177 previous studies using similar doses of NO_3^- (e.g., Ref. 20). Ingestion of BRJ containing twice as 178 much NO_3^- (i.e., 400 µmol/kg) resulted in almost exactly double the increase in plasma NO_3^- and 179 NO₂⁻ concentration (Table 1, Fig. 1A and 1B). In contrast, the level of NO in breath increased 180 less after the higher vs. the lower dose of NO_3^- (Table 1, Fig. 1C), although it was still elevated 181 compared to the placebo trial. Plasma 3-NT concentrations initially decreased then gradually 182 increased during all three trials (P<0.05), but these changes tended to be greater during the 183 placebo and low dose trials versus the high dose trial (Table 1, Fig. 1D).

184 Muscle contractile function: There were no significant effects of NO_3^{-1} ingestion on knee 185 extensor peak torque, and hence peak power, at low to moderate angular velocities (i.e., at 0, 186 1.57, 3.14, or 4.71 rad/s; Table 2). In keeping with our previous results (16), however, ingestion 187 of BRJ containing a moderate amount of NO_3^- (i.e., 200 µmol/kg) resulted in a significant 188 increase in peak torque, and hence peak power, at the highest velocity tested (i.e., 6.28 rad/s) 189 (Table 2). This beneficial effect of acute NO_3^- supplementation on muscle contractile function 190 was lost when the NO_3^- dose was doubled to 400 μ mol/kg (Table 2). Correspondingly, Pmax (in 191 W/kg) as calculated from these data was significantly higher (P<0.05) after the low dose 192 (3.9 ± 0.4) compared to the placebo (3.7 ± 0.4) or high dose (3.7 ± 0.4) . Vmax (in rad/s) also tended 193 higher (P=0.08) in the low (11.9 \pm 0.7) compared to the placebo (10.8 \pm 0.8) or high (11.2 \pm 0.8) 194 trials. Eight out of nine subjects (including the one man) achieved a higher Pmax and Vmax after 195 ingestion of the lower vs. the higher dose of NO₃⁻ (Figs. 2A-D).

Hemodynamics: Heart rate did not change significantly over time or in response to ingestion of varying amounts of NO_3^- (Table 3). Systolic and mean blood pressure, on the other hand, decreased significantly over time (both P<0.01 for main effect), with such changes tending to be greatest in the high dose trial (Table 3). However, neither the treatment main effects nor the treatment x time interaction effects were statistically significant. Diastolic blood pressure did not change significantly with either time or treatment.

202 Discussion

The purpose of the present study was to determine the effect of varying doses of dietary NO_3^- on changes in muscle contractile function and blood pressure in healthy older individuals. We found that a moderate dose of NO_3^- (i.e., 200 µmol/kg) resulted in measurable improvements in maximal knee extensor speed and power, but no significant changes in blood pressure. A larger

dose of NO_3^- (i.e., 400 µmol/kg) also did not significantly alter blood pressure, whereas muscle speed and power actually regressed towards, and in some individuals even below, baseline values. This is the first dose-response study of the effects of acute dietary NO_3^- supplementation on muscle contractile function in any population, and the first to specifically examine changes in blood pressure in older subjects.

212 We have previously demonstrated that dietary NO_3^- supplementation can enhance muscle 213 contractility in a variety of subject populations (11-14). This includes healthy elderly men and 214 women, in whom acute intake of 13.4 ± 0.5 mmol ($182\pm10 \mu$ mol/kg) of NO₃⁻ increased maximal 215 knee extensor speed and power by 11 ± 2 and $4\pm 4\%$, respectively (16). The results of the present 216 study are similar, in that Vmax and Pmax improved by 8 ± 4 and $7\pm3\%$, respectively, after 217 ingestion of BRJ containing 200 μ mol/kg of NO₃⁻. The somewhat greater increase in Pmax in the 218 present investigation vs. our previous study could be due to the slightly larger dose of NO_3^{-1} 219 provided. Indeed, in our previous study we observed that individuals who received less than 220 ~150 μ mol/kg of NO₃⁻ were less likely to show significant improvements in muscle function 221 (unpublished observations). Alternatively, it could be due to the greater percentage of women in 222 the present study (i.e., 89 vs. 50%), as we have found that women tend to be more likely to 223 benefit from NO_3^{-1} intake (12). Regardless, as previously discussed these improvements in muscle 224 function are substantial relative to their normal rate of decline with aging, and in fact are roughly 225 comparable to those resulting from several months of traditional resistance exercise training (cf. 226 Ref. 26 for review). As such, dietary NO_3^- supplementation could potentially have a measurable 227 impact on the functional capacity (e.g., walking speed, chair rise time, stair climbing ability) of 228 older persons during daily life, thus minimizing the risk of disability and dependence.

229 Given the latter, it is imperative to determine the optimal dose (and timing and source, 230 i.e., BRJ vs. a salt) of NO₃⁻ for enhancing muscle contractile function in older persons. Previous 231 dose-response studies in younger untrained or moderately-trained individuals have found that 232 providing 6-10 mmol (roughly 100-150 μ mol/kg) of NO₃⁻ is generally sufficient to improve 233 economy and/or performance during endurance exercise (20,27-29), with no further 234 improvements at higher doses (i.e., up to 16.8 mmol, or ~225 µmol/kg) (20). As implied above, 235 however, it appears that somewhat higher doses of NO_3^- may be required to increase muscle 236 speed and power, at least in older men and women. Thus, in addition to studying a NO_3^- dose of 237 200 µmol/kg, we also tested subjects after they had consumed double this dose, i.e., 400 238 μ mol/kg. Based on our previous research and that of Wylie et al. (20), we anticipated that this 239 would result in a quantitatively-similar improvement in muscle contractile function, i.e., that both 200 and 400 µmol/kg would fall on a plateau in the dose-response relationship. 240 241 Surprisingly, however, both Vmax and Pmax actually regressed at the higher dose, such that on 242 average they were not significantly different from the placebo trial. This pattern was highly 243 consistent across subjects, with all but one of the subjects performing best with the lower dose, 244 and several of the subjects actually performing worse following the higher dose than during the 245 placebo trial. To our knowledge, this is the first study to demonstrate a possible impairment in 246 exercise performance following ingestion of dietary NO_3^- , although both Larsen et al. (30) and 247 Bescós et al. (31) have previously reported that NO_3^- ingestion can reduce VO_2 max.

The mechanism responsible for the above unanticipated finding is not clear. It does not, however, appear to be due to failure of the higher dose of NO_3^- to further augment plasma $NO_3^$ and NO_2^- levels, as both rose almost exactly twice as much following the 400 vs. the 200 µmol/kg dose. This is consistent with the essentially complete bioavailability of NO_3^- from

252 ingested vegetables (32). Interestingly, however, the availability of NO itself, at least as 253 measured in the breath, rose less after the higher vs. the lower dose, and thus was significantly 254 lower in the former vs. the latter experiments. We therefore measured plasma 3-NT 255 concentrations, as another marker of the rate of NO production but also to determine whether the 256 higher dose of NO_3^- (which averaged 28.7±2.7 mmol) resulted in "peaking over" of muscle 257 contractile function due to an increase in nitrosative stress. This possibility was suggested by the 258 recent results of Gholami et al. (33), who reported that ingestion of 24, but not 8 or 16, mmol of 259 NO_3^{-1} resulted in a dramatic increase in plasma peroxynitrite levels in well-trained subjects 260 following a maximal incremental exercise test. In the present study, however, the pattern of 261 change in plasma 3-NT instead generally resembled that of breath NO, i.e., tending to increase 262 slightly after the lower dose but decrease slightly after the higher dose of NO₃.

We interpret the above findings as follows: the lower dose of NO₃⁻ significantly increased 263 264 plasma NO_3^- concentrations, which led to a rise in plasma (and presumably tissue (34)) NO_2^- 265 levels, and hence an increase in NO bioavailability. As a result of the latter, both muscle 266 contractile function (i.e., Vmax and Pmax) and plasma 3-NT concentrations were elevated (the 267 latter insignificantly) compared to the placebo trial. Conversely, the higher dose of NO_3^- resulted 268 in even greater increases in plasma NO₃⁻ and NO₂⁻ concentrations, but NO itself actually 269 increased less than after the lower dose, ostensibly as a result of NO_3^- outcompeting NO_2^- for 270 reduction by XOR. Consequently, muscle speed and power did not change significantly, whereas 271 plasma 3-NT concentrations actually tended to decline. This scenario, which is shown 272 schematically in Figure 3, is partially based on the observations of Damacena-Angelis et al. (35), 273 who found that higher concentrations of NO₃⁻ can inhibit XOR-mediated reduction of NO₂⁻ to NO, and thus partially attenuate the blood pressure lowering effect of NO_2^- in rats. Although 274

speculative, the above hypothesis could explain the present observations. Alternatively, it is possible that the high concentrations of NO_3^- and/or NO_2^- present after ingestion of the higher dose led to a direct inhibitory effect on muscle contractile function, e.g., by enhancing transnitrosylation of myosin (36). This would not, however, account for the lower NO levels observed following ingestion of the higher dose of NO_3^- .

In contrast to the improvements in muscle speed and power observed following ingestion 280 281 of the lower dose of NO_3^{-} , blood pressure was unaltered by either the lower or the higher dose. 282 This finding is consistent with a recent meta-analysis by Siervo et al. (18) but runs counter to the 283 results of other studies of older subjects (37-39). The reason for these divergent results is 284 uncertain. The amount of NO₃⁻ provided in the present experiments is much higher than used in 285 these previous studies, such that an inadequate dose can seemingly be ruled out. It is possible 286 that the subjects we studied were resistant to the potential blood pressure-lowering effects of 287 dietary NO_3^- due to excessive oxidative stress, since NO_3^- plus ascorbic acid but not NO_3^- alone 288 has been reported to reduce systolic and mean arterial blood pressure in older adults (40). It is 289 also possible, however, that the failure to detect a statistically-significant NO_3 -induced reduction 290 in blood pressure in the present study is simply a type 2 statistical error, due to the well-known 291 variability of blood pressure measurements combined with a relatively small number of subjects. 292 This is so because 1) changes in blood pressure from baseline were numerically greater after 293 NO_3^- ingestion (i.e., -8 ± 3 , -11 ± 4 , and -16 ± 4 , -1 ± 2 , -2 ± 2 , and -4 ± 2 , and -4 ± 2 , -5 ± 2 , and -8 ± 2 294 mmHg for systolic, diastolic, and mean arterial pressure in the placebo, 200 µmol/kg, and 400 295 µmol/kg trials, respectively), and 2) post-hoc analysis of the data demonstrated that, given the 296 observed effect sizes, the achieved powers (i.e., $1-\beta$) with n=9 subjects were only 0.64, 0.67, and 297 0.83, respectively.

298 There are both strengths and weaknesses to the present study. A major strength is the use 299 of a highly-reliable method for assessing maximal muscle contractile properties, even in older 300 subjects. For example, as calculated from the ANOVA the intraclass correlation coefficient 301 (ICC) for Pmax was 0.98. This helps explain why we were able to detect statistically-significant 302 changes in muscle contractile function but not in, e.g., systolic blood pressure (ICC=0.70). 303 Another strength is that, unlike in previous dose-response studies (20,27-29), in the present 304 experiments the dose of NO_3^- was adjusted relative to body mass, thus at least theoretically 305 minimizing inter-subject variability in peak plasma NO_3^{-1} concentrations due to differences in the 306 volume of distribution. At the same time, we kept the volume of BRJ the same across trials, thus 307 eliminating differences in the amount of other potentially biologically-active compounds (e.g., 308 carotenoids, betalains, bioflavonoids, ascorbic acid) as a source of variability. As discussed 309 above, a weakness of our study is that it was slightly underpowered to detect possible differences 310 in blood pressure due to NO₃⁻ ingestion. Another weakness is that by studying only two doses of 311 NO_3^{-} , i.e., 200 and 400 μ mol/kg, it is not possible to determine whether the optimal dose is 312 somewhat less than 200 µmol/kg or somewhere between 200 and 400 µmol/kg. At a minimum, 313 however, the present data provide a starting point for further experiments.

In summary, in the present study we have examined the dose-response relationship between dietary NO_3^- supplementation and changes in both muscle contractile function and blood pressure in healthy older subjects. We found that although blood pressure was unchanged, ingestion of a lower, but not a higher, dose of NO_3^- significantly increased maximal knee extensor power, with these divergent results seemingly reflecting the failure of the higher dose to sufficiently elevate NO bioavailability. Future studies should use the tools and approaches

- 320 commonly employed in pharmaceutical development (e.g., pharmacokinetic-pharmacodynamic
- 321 modeling) to further refine this possible treatment for muscle dysfunction in older persons.

322 Conflicts of Interest and Source of Funding

323 This work was supported by grants from the Office of the Vice Provost for Research at Indiana 324 University Purdue University Indianapolis and the National Institute on Aging (R21 AG053606) 325 to A.R. Coggan; the National Heart, Lung, and Blood institute (R34 HL138253) to A.R. Coggan 326 and Linda R. Peterson; the National Institute on Diabetes, Digestive, and Kidney Diseases (K23) 327 DK102824) to R.N. Moorthi, the National Institute on Arthritis and Musculoskeletal and Skin 328 Disease (P30 AR072581) to Sharon Mo; and the National Center for Advancing Translational 329 Sciences (UL1 TR002529) to Anantha Shekhar. For the remaining authors no conflicts of 330 interest are declared. The contents of this article are solely the responsibility of the authors and 331 does not necessarily represent the official view of the National Institutes of Health or the 332 American College of Sports Medicine. The results of the study are presented clearly, honestly, 333 and without fabrication, falsification, or inappropriate data manipulation.

334 **References**

335	1.	Roberts AW, Ogunwole SU, Blakeslee L, Rabe MA. U.S. Census Bureau, American
336		Community Survey Reports, ACS-38, The Population 65 Years and Older in the United
337		States: 2016, U.S. Government Publishing Office, Washington, DC, 2018.
338		
339	2.	Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA,
340		Wallace RB. A short physical performance battery assessing lower extremity function:
341		association with self-reported disability and prediction of mortality and nursing home
342		admission. J Gerontol. 1994;49(2):M85-M94. https://doi.org/10.1093/geronj/49.2.m85
343		
344	3.	Roshanravan B, Patel KV, Fried LF, Robinson-Cohen C, de Boer IH, Harris T, Murphy RA,
345		Satterfield S, Goodpaster BH, Shlipak M, Newman AB, Kestenbaum B; Health ABC study.
346		Association of muscle endurance, fatigability, and strength with functional limitation and
347		mortality in the Health Aging and Body Composition study. J Gerontol A Biol Sci Med Sci.
348		2017;72(2):284-291. https://doi.org/10.1093/gerona/glw210
349		
350	4.	Reid KF, Fielding RA. Skeletal muscle power: A critical determinant of physical functioning
351		in older adults. Exerc Sports Sci Rev. 2012:40(1):4-40.
352		https://doi.org/10.1097/JES.0b013e31823b5f13
353		
354	5.	da Rosa Orssatto LB, Wiest MJ, Diefenthaeler F. Neural and musculotendinous mechanisms
355		underpinning age-related force reductions. Mech Ageing Dev 2018;175(10):17-23.

356 <u>https://doi.org/10.1016/j.mad.2018.06.005</u>

2	5	7
Э	J	1

358	6.	Thompson BJ, Conchola EC, Palmer TB, Stock MS. Effects of aging on maximal and rapid
359		velocity capacities of the leg extensors. Exp Gerontol. 2014;58(10):128-131.
360		https://doi.org/10.1016/j.exger.2014.07.019
361		
362	7.	Valour D, Ochala J, Ballay Y, Pousson M. The influence of ageing on the force-velocity-
363		power characteristics of human elbow flexor muscles. Exp Gerontol. 2003;38(4):387-395.
364		https://doi.org/10.1016/s0531-5565(02)00265-6
365		
366	8.	Toji H, Kaneko M. Effects of aging on force, velocity, and power in the elbow flexors of
367		males. J Physiol Anthropol. 2007;26(11):587-592. https://doi.org/10.2114/jpa2.26.587
368		
369	9.	Pojednic RM, Clark DJ, Patten C, Reid K, Phillips EM, Fielding RA. The specific
370		contribution of force and velocity to muscle power in older adults. Exp Gerontol.
371		2012;47(8):608-612. https://doi.org/0.1016/j.exger.2012.05.010
372		
373	10	. Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in
374		physiology and therapeutics. Nat Rev Drug Discov. 2008;7(2):156-167.
375		https://doi.org/10.1038/nrd2466
376		
377	11	. Coggan AR, Leibowitz JL, Kadkhodayan A, et al. Effect of acute dietary nitrate intake on
378		knee extensor speed and power in healthy men and women. Nitric Oxide. 2015;48(8):16-21.
379		https://doi.org/10.1016/j.niox.2014.08.014

18

2	0	n
3	0	υ

381	12. Coggan AR, Broadstreet SR, Mikhalkova D, et al. Dietary nitrate-induced increases in
382	human muscle power: high versus low responders. Physiol Rep. 2018;6(2):e13575,
383	https://doi.org/10.14814/phy2.13575
384	
385	13. Rimer EG, Peterson LR, Coggan AR, Martin JC. Acute dietary nitrate supplementation
386	increases maximal cycling power in athletes. Int J Sports Physiol Perf. 2016;11(6):715-720.
387	https://doi.org/10.1123/ijspp.2015-0533
388	
389	14. Coggan AR, Leibowitz JL, Anderson Spearie C, et al. Acute dietary nitrate intake improves
390	muscle contractile function in patients with heart failure: a double-blind, placebo-controlled,
391	randomized trial. Circ Heart Fail. 2015;8(5):914-920.
392	https://doi.org/10.1161/CIRCHEARTFAILURE.115.002141
393	
394	15. Coggan AR, Peterson LR. Dietary nitrate influences the contractile properties of human
394 395	15. Coggan AR, Peterson LR. Dietary nitrate influences the contractile properties of human muscle.ExercSportSciRev.2018;46(4):254-261.
394 395 396	15. Coggan AR, Peterson LR. Dietary nitrate influences the contractile properties of human muscle. Exerc Sport Sci Rev. 2018;46(4):254-261. https://doi.org/10.1249/JES.0000000000167
394395396397	15. Coggan AR, Peterson LR. Dietary nitrate influences the contractile properties of human muscle. Exerc Sport Sci Rev. 2018;46(4):254-261. https://doi.org/10.1249/JES.00000000000167
 394 395 396 397 398 	 15. Coggan AR, Peterson LR. Dietary nitrate influences the contractile properties of human muscle. Exerc Sport Sci Rev. 2018;46(4):254-261. https://doi.org/10.1249/JES.00000000000167 16. Coggan AR, Hoffman RL, Gray DA, Moorthi RN, Thomas DP, Leibowitz JL, Thies D,
 394 395 396 397 398 399 	 15. Coggan AR, Peterson LR. Dietary nitrate influences the contractile properties of human muscle. Exerc Sport Sci Rev. 2018;46(4):254-261. https://doi.org/10.1249/JES.000000000000000000000000000000000000
 394 395 396 397 398 399 400 	 15. Coggan AR, Peterson LR. Dietary nitrate influences the contractile properties of human muscle. Exerc Sport Sci Rev. 2018;46(4):254-261. https://doi.org/10.1249/JES.000000000000167 16. Coggan AR, Hoffman RL, Gray DA, Moorthi RN, Thomas DP, Leibowitz JL, Thies D, Peterson LR. A single dose dietary of nitrate increases maximal muscle speed and power in healthy older men and women. <i>J Gerontol A Biol Sci Med Sci.</i> 2020; 75(6):1154-1160.
 394 395 396 397 398 399 400 401 	 15. Coggan AR, Peterson LR. Dietary nitrate influences the contractile properties of human muscle. Exerc Sport Sci Rev. 2018;46(4):254-261. https://doi.org/10.1249/JES.000000000000000000000000000000000000

403	17. Ashor AW, Lara J, Siervo M. Medium-term effects of dietary nitrate supplementation on					
404	systolic and diastolic blood pressure in adults: a systematic review and meta-analysis. J					
405	Hypertens. 2017;35(7):1353-1359. https://doi.org/10.1097/hjh.000000000001305					
406						
407	18. Siervo M, Lara J, Jajja A, Sutyarjoko A, Ashor AW, Brandt K, Qadir O, Mathers JC,					
408	Benjamin N, Winyard PG, Anning C, Shore A, Gilchrist M. Ageing modifies the effects of					
409	beetroot juice supplementation on 24-hour blood pressure variability: An individual					
410	participant meta-analysis. <i>Nitric Oxide</i> . 2015:47(1):97-105.					
411	https://doi.org/10.1016/j.niox.2015.04.007					
412						
413	19. Li L, Wang H, Hu L, Zhao B, Fan Z, Zhang C, Wang J, Wang S. Age associated decrease of					
414	sialin in salivary glands. Biotech Histochem 2018;93(7):505-511.					
415	https://doi.org/10.1080/10520295.2018.1463453					
416						
417	20. Wylie LJ, Kelly J, Bailey SJ, Blackwell JR, Skiba PF, Winyard PG, Jeukendrup AE,					
418	Vanhatalo A, Jones AM. Beetroot juice and exercise: pharmacodynamic and dose-response					
419	relationships. J Appl Physiol. 2013;115(3):325-336.					
420	https://doi.org/10.1152/japplphysiol.00372.2013					
421						
422	21. Lundberg JO, Weitzberg E, Lundberg JM, Alving K. Intragastic nitric oxide production in					
423	humans: measurements in expelled air. Gut 1994;35(11):1543-1546.					
424	https://doi.org/10.1136/gut.35.11.1543					
425						

426	22. Obach RS, Huynh P, Allen MC, Beedham C. Human liver aldehyde oxidase: inhibition by
427	239 drugs. J Clin Pharmacol. 2004;44(1):7-19. https://doi.org/10.1177/0091270003260336
428	
429	23. Govoni M, Jansson EA, Weitzberg E, Lundberg JO. The increase in plasma nitrite after a
430	dietary nitrate load is markedly attenuated by an antibacterial mouthwash. Nitric Oxide.
431	2008;19(4):333-337. https://doi.org/10.1016/j.niox.2008.08.003
432	
433	24. Webb DJ, Freestone S, Allen MJ, Muirhead GJ. Sildenafil citrate and blood-pressure-
434	lowering drugs: results of drug interaction studies with an organic nitrate and a calcium
435	antagonist. Am J Cardiol. 1999;83(5A):21C-28C. <u>https://doi.org/10.1016/s0002-</u>
436	9149(99)00044-2
437	
438	25. Coggan AR, Broadstreet SR, Mahmood K, Mikhalkova D, Madigan M, Bole I, Leibowitz JL,
439	Thomas DP, Thies D, Peterson LR. Dietary nitrate increases VO ₂ peak and performance but
440	does not alter ventilation or efficiency in patients with heart failure with reduced ejection
441	fraction. J Card Fail. 2018; 24(2):65-73. https://doi.rog/10.1016/j.cardfail.2017.09.004
442	
443	26. Steib S, Schoene D, Pfeifer K. Dose-response relationship of resistance training in older
444	adults: a meta-analysis. Med Sci Sports Exerc. 2010;42(5):902-914.
445	https://10.1249/MSS.0b013e3181c34465
446	
447	27. Flueck JL, Bogdanova A, Mettler S, Perret C. Is beetroot juice more effective than sodium
448	nitrate? The effects of equimolar nitrate dosages of nitrate-rich beetroot juice and sodium

- 449 nitrate on oxygen consumption during exercise. *Appl Physiol Nutr Metab.* 2016;41(4):421-
- 450 429. <u>https://doi.org/10.1139/apnm-2015-0458</u>
- 451
- 452 28. Hoon MW, Jones AM, Johnson NA, Blackwell JR, Broad EM, Lundy B, Rice AJ, Burke
- 453 LM. The effect of variable doses of inorganic nitrate-rich beetroot juice on simulating 2,000-
- 454 m rowing performance in trained athletes. *Int J Sports Physiol Perform.* 2014;9(4):615-620.
- 455 <u>https://doi.org/10.1123/ijspp.2013-0207</u>
- 456
- 457 29. Peeling P, Cox GR, Bullock N, Burke LM. Beetroot juice improves on-water 500 m time-458 trial performance, and laboratory-based paddling economy in national and international-level 459 kayak athletes. Int Sport Nutr Exerc Metab. 2015;25(3):278-284. J460 https://doi.org/10.1123/ijsnem.2014-0110
- 461

30. Larsen FJ, Wietzberg E, Lundberg JO, Ekblom B. Dietary nitrate reduces maximal oxygen
consumption while maintaining work performance in maximal exercise. *Free Radic Biol Med.* 2010;48(2):342-347. <u>https://doi.org/10.1016/j.freeradbiomed.2009.11.006</u>

465

31. Bescós R, Rodríguez FA, Iglesias X, Ferrer MD, Iborra E, Pons A. Acute administration of
inorganic nitrate reduces VO(2peak) in endurance athletes. *Med Sci Sports Exerc*.
2011;43(10):1979-1986. <u>https://doi.org/10.1249/MSS.0b013e318217d439</u>

469

470	32. van Velzen AG, Sips AJAM, Schothorst RC, Lambers AC, Meulenbelt J. The oral
471	bioavailability of nitrate from nitrate-rich vegetables in humans. Toxicol Lett.
472	2008;181(3):177-181. https://doi.org/10.1016/j.toxlet.2008.07.019
473	
474	33. Gholami F, Rahamini L, Amirnezhad F, Cheraghi K. High doses of sodium nitrate prior to
475	exhaustive exercise increases plasma peroxynitrite levels in well-trained subjects:
476	randomized, double-blinded, crossover study. Appl Physiol Nutr Metab. 2019;44(12):1305-
477	1310. <u>https://doi.org/10.1139/apnm-2018-0816</u>
478	
479	34. Wylie LJ, Park JW, Vanhatalo A, Kadach S, Black MI, Stoyanov Z, Schechter AN, Jones
480	AM, Piknova B. Human skeletal muscle nitrate store: influence of dietary nitrate
481	supplementation and exercise. J Physiol. 2019;597(23):5565-5576.
482	https://doi.org/10.1113/JP278076
483	
484	35. Damacena-Angelis C, Oliveira-Paula GH, Pinheiro LC, Crevelin EJ, Portella RL, Moraes
485	LAB, Tanus-Santos JE. Nitrate decreases xanthine oxidoreductase-mediated nitrite reductase
486	activity and attenuates vascular and blood pressure responses to nitrite. Redox Biol.
487	2017;12(8):291-299. https://doi.org/10.1016/j.redox.2017.03.003
488	
489	36. Nogueira L, Figueiredo-Freitas C, Casimiro-Lopes G, Magdesian MH, Assreuy J, and
490	Sorenson MM. Myosin is reversibly inhibited by S-nitrosylation. Biochem J. 2009;
491	424(2):221-231. https://doi.org/10.1042/BJ20091144
492	

493	37. Kelly	J, Fulford	J, Vanhatalo	A, et al. E	effects of sh	ort-term dieta	ry nitrate suppler	nentation
494	on blo	od pressure	e, O ₂ uptake	kinetics, an	d muscle ar	nd cognitive fu	unction in older a	dults. Am
495	J	Physiol	Regul	Integr	Comp	Physiol.	2013;304(2):F	R73–R83.
496	<u>https:/</u>	//doi.org/10	.1152/ajpreg	<u>u.00406.20</u>	<u>12</u>			
497								
498	38. Kim I	DJ, Roe CA	, Somani YH	3, Moore D	J, Barrett M	IA, Flanagan	M, Kim-Shapiro I	OB, Basu
499	S, Mu	ller MD, P	roctor DN. E	Effects of a	cute dietary	nitrate supple	ementation on aor	tic blood
500	pressu	res and p	oulse wave	characteris	stics in po	ost-menopausa	l women. Nitri	c Oxide.
501	2019;	85(4):10-16	. https://doi.o	org/10.1016	<u>5/j.niox.201</u>	9.01.008		
502								
503	39. Hughe	es WE, U	eda K, Tr	eichler DI	P, Casey I	DP. Effects	of acute dietar	y nitrate
504	supple	ementation	on aortic blo	od pressure	e and aortic	augmentation	index in young a	and older
505	adults	. Nitric Oxi	de. 2016;59(9):21-27. <u>h</u> i	ttps://doi.or	g/10.1016/j.ni	ox.2016.06.007	
506								
507	40. Ashor	· AW, Shan	non OM, W	erner A-D,	Sciallo F, O	Giallard CN, G	Cassel KS, Seal C	J, Zheng
508	D, Ma	thers JC, S	iervo M. Eff	fects of ino	rganic nitra	te and vitamir	n C co-supplemen	tation on
509	blood	pressure a	nd vascular	function in	i younger a	nd older heal	lthy adults: A rai	ndomised
510	double	e-blind	crossover	trial	. Clin	Nutr.	2019;39(3):	708-717.
511	https:/	//doi.org/10	.1016/j.clnu.	2019.03.00	<u>6</u>			

Table 1. Effect of varying doses of dietary NO_3^- on plasma NO_3^- , plasma NO_2^- , breath NO, and 512

513 plasma 3-nitrotyrosine in healthy older subjects.

			Time of me	easurement	
	Dose of NO ₃ ⁻	Due in costion	1 h post	2 h post	10 min post
	(µmol/kg)	Pre <u>ingestion</u>	ingestion	ingestion	<u>exercise</u>
Diagma NO -	0	55±10	57±5	67±6	66±5
Plasma NO_3	200	40±5	523±52 [‡]	624±53 [‡]	$628 \pm 47^{\ddagger}$
(μmoi/L)	400	34±5	793±73 ^{‡¶}	1184±89 ^{‡¶}	1296±94 ^{‡¶}
Diama NO -	0	0.31±0.05	0.30±0.02	0.33±0.04	0.35±0.05
Plasma NO_2	200	0.31±0.04	0.46 ± 0.07	$0.53 \pm 0.07^{*}$	0.82±0.18
(µmol/L)	400	0.34±0.06	0.48 ± 0.06	$0.95{\pm}0.18^{*}$	$1.22\pm0.15^{*}$
	0	19±3	22±3	25±3	21±3
Breath NO (ppb)	200	18±3	39±6*	43±7*	$50\pm10^*$
	400	18±3	$31\pm4^{\dagger}$	$36\pm4^{\dagger}$	36±6*
	0	177±20	153±18	170±19	217±27
3-INItrotyrosine	200	170±22	158±19	176±23	216±27
(nmol/L)	400	237±25	209±22	198±26	250±34

Values are mean±SE for n=9. Significantly different from 0 µmol/kg dose: *P<0.05, [†]P<0.01, 514 [‡]P<0.001. Significantly different from 200 μ mol/kg dose: [§]P<0.05, [¶]P<0.001. 515

516 Table 2. Effect of varying doses of dietary NO₃ on peak knee extensor torque and power as a

517 function of velocity in healthy older subjects.

		Angular velocity (rad/s)					
	Dose of NO ₃ ⁻	<u>0</u>	<u>1.57</u>	<u>3.14</u>	<u>4.71</u>	<u>6.28</u>	
	0	1.79±0.15	1.21±0.10	0.91±0.06	0.75±0.06	0.55±0.06	
Peak torque (Nm/kg)	200	1.86±0.15	1.24±0.07	0.92±0.06	0.78 ± 0.06	$0.61\pm0.06^{\dagger}$	
	400	1.78±0.12	1.24±0.07	0.90±0.05	0.74 ± 0.06	0.56±0.06	
	0	0.00 ± 0.00	1.97±0.15	2.91±0.22	3.59±0.30	3.46±0.45	
Peak power (W/kg)	200	0.00 ± 0.00	1.95±0.11	2.89±0.20	3.69±0.27	3.83±0.37 [†]	
	400	0.00 ± 0.00	1.94±0.11	2.84±0.17	3.48±0.28	3.49±0.39	

518 Values are mean \pm SE for n=9. Significantly different from 0 or 400 µmol/kg doses: [†]P<0.01.

Table 3. Effect of varying doses of dietary NO₃ on heart rate and blood pressure in healthy older 519

520 subjects.

	Time of measurement				
	Dose of NO ₃ ⁻	Pre <u>ingestion</u>	1 h post	2 h post	10 min post
			ingestion	ingestion	exercise
Heart rate (beats/min)	0	73±4	72±3	70±3	73±3
	200	71±4	74±3	70±3	73±2
	400	72±3	70±3	71±3	74±3
Systolic blood pressure (mmHg)	0	131±5	122±4	122±3	125±4
	200	130±4	122±6	121±5	119±6
	400	134±4	121±4	118±5	118±6
Diastolic blood pressure (mmHg)	0	70±2	68±2	68±3	69±2
	200	69±4	67±3	67±3	68±4
	400	69±3	62±3	64±4	65±3
Mean arterial pressure (mmHg)	0	90±2	86±2	86±2	87±2
	200	90±3	85±3	85±3	85±3
	400	90±3	82±3	82±3	82±3

Values are mean±SE for n=9. 521

522 **Figure legends**

523

Figure 1. Changes (Δ) in plasma nitrate (NO₃⁻; *panel A*), nitrite (NO₂⁻; *panel B*), breath nitric oxide (NO; *panel C*), and plasma 3-nitrotyrosine (3-NT; *panel D*) in response to varying doses of dietary NO₃⁻ in healthy older subjects. Values are mean±SE for n=9. Significantly different from 0 µmol/kg dose: *P<0.05, ‡P<0.001. Significantly different from 200 µmol/kg dose: \$P<0.05, 528 \$P<0.001.

529

Figure 2. Individual absolute and relative changes (Δ) in maximal knee extensor power (Pmax; *panels A and B*) and velocity (Vmax; *panels C and D*) in response to varying doses of dietary nitrate (NO₃⁻) in healthy older subjects.

533

534 Figure 3. Proposed explanation for the effect of varying doses of dietary nitrate (NO₃) on muscle 535 contractile function in healthy older subjects. A lower dose of NO₃⁻ (i.e., 200 µmol/kg) is 536 hypothesized to result in a significant increase in muscle NO₃⁻ concentration, which is reduced 537 by xanthine oxidoreductase (XOR) to nitrite (NO_2) and then to nitric oxide (NO), leading to 538 significant improvements in maximal knee extensor power (Pmax) and velocity (Vmax) and also 539 to an increase in 3-nitrotyrosine (3-NT) formation. In contrast, a higher dose of NO_3^- (i.e., 540 400 µmol/kg) actually results in less of an increase in NO production, due to substrate 541 competition between NO_3^- and NO_2^- for XOR. As a result, Pmax, Vmax, and 3-NT are 542 diminished. unchanged, possibly or even











Low Dose

$$\uparrow NO_3^- \xrightarrow{XOR} \uparrow NO_2^- \xrightarrow{XOR} \uparrow NO$$

High Dose

